(VIANEWS) – Assured Guaranty Ltd. (AGO), TG Therapeutics (TGTX), Ligand Pharmaceuticals Incorporated (LGND) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Assured Guaranty Ltd. (AGO)
142.7% sales growth and 13.25% return on equity
Assured Guaranty Ltd., through its subsidiaries, provides credit protection products to public finance, infrastructure, and structured finance markets in the United States and internationally. The company operates in two segments, Insurance and Asset Management. It offers financial guaranty insurance that protects holders of debt instruments and other monetary obligations from defaults in scheduled payments. The company insures and reinsures various debt obligations, including bonds issued by the United States state, governmental authorities, or municipal governmental authorities; and notes issued to finance infrastructure projects. It also insures and reinsures various types of the U.S. public finance obligations, such as general obligation, tax-backed, municipal utility, transportation, healthcare, higher education, infrastructure, housing revenue, investor-owned utility, renewable energy, and other public finance bonds; non-U.S. public finance obligations comprising regulated utilities, infrastructure finance, sovereign and sub-sovereign, renewable energy bonds, pooled infrastructure, and other public finance obligations; and the U.S. and non-U.S. Structured finance obligations, including residential mortgage-backed securities, insurance securitization obligations, consumer receivables securities, pooled corporate obligations, financial products, and other structured finance securities. In addition, the company provides asset management services comprising investment advisory services, including management of collateralized loan obligations and opportunity funds to outside investors. It markets its financial guaranty insurance directly to issuers and underwriters of public finance and structured finance securities, as well as to investors in such obligations. Assured Guaranty Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Earnings Per Share
As for profitability, Assured Guaranty Ltd. has a trailing twelve months EPS of $12.21.
PE Ratio
Assured Guaranty Ltd. has a trailing twelve months price to earnings ratio of 6.29. Meaning, the purchaser of the share is investing $6.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.25%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 21, 2024, the estimated forward annual dividend rate is 1.24 and the estimated forward annual dividend yield is 1.62%.
Moving Average
Assured Guaranty Ltd.’s worth is below its 50-day moving average of $78.58 and under its 200-day moving average of $79.19.
Revenue Growth
Year-on-year quarterly revenue growth declined by 39.2%, now sitting on 834M for the twelve trailing months.
Sales Growth
Assured Guaranty Ltd.’s sales growth is 112% for the ongoing quarter and 142.7% for the next.
2. TG Therapeutics (TGTX)
123.8% sales growth and 87.78% return on equity
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.
Earnings Per Share
As for profitability, TG Therapeutics has a trailing twelve months EPS of $0.68.
PE Ratio
TG Therapeutics has a trailing twelve months price to earnings ratio of 33.25. Meaning, the purchaser of the share is investing $33.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 87.78%.
3. Ligand Pharmaceuticals Incorporated (LGND)
49.9% sales growth and 5.85% return on equity
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.
Earnings Per Share
As for profitability, Ligand Pharmaceuticals Incorporated has a trailing twelve months EPS of $2.33.
PE Ratio
Ligand Pharmaceuticals Incorporated has a trailing twelve months price to earnings ratio of 45.41. Meaning, the purchaser of the share is investing $45.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.85%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 57.5%, now sitting on 133.48M for the twelve trailing months.
4. Tidewater (TDW)
28.3% sales growth and 16.18% return on equity
Tidewater Inc., together with its subsidiaries, provides offshore support vessels and marine support services to the offshore energy industry through the operation of a fleet of marine service vessels worldwide. It provides services in support of offshore oil and gas exploration, field development, and production, as well as windfarm development and maintenance, including towing of and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workover, and production activities; offshore construction, and seismic and subsea support; geotechnical survey support for windfarm construction; and various specialized services, such as pipe and cable laying. The company operates anchor handling towing supply vessels, platform supply vessels, crew boats, utility vessels, and offshore tugs. The company serves integrated and independent oil and gas exploration, field development, and production companies; mid-sized and smaller independent exploration and production companies; foreign government-owned or government-controlled organizations, and other related companies; offshore drilling contractors; and other companies, such as offshore construction, windfarm development, diving, and well stimulation companies. Tidewater Inc. was incorporated in 1956 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Tidewater has a trailing twelve months EPS of $3.03.
PE Ratio
Tidewater has a trailing twelve months price to earnings ratio of 29.23. Meaning, the purchaser of the share is investing $29.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.18%.
Yearly Top and Bottom Value
Tidewater’s stock is valued at $88.56 at 11:22 EST, way below its 52-week high of $111.42 and way above its 52-week low of $54.53.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 98% and 175.7%, respectively.
Sales Growth
Tidewater’s sales growth is 20.5% for the ongoing quarter and 28.3% for the next.
5. Great Elm Capital Corp. (GECC)
23.2% sales growth and 9.31% return on equity
Great Elm Capital Corporation is a business development company which specializes in loan and mezzanine, middle market investments. The fund prefers to invest in media, commercial services and supplies, healthcare, telecommunication services, communications equipment. It typically makes equity investments between $3 million and $10 million in companies with revenues between $3 million and $75 million.
Earnings Per Share
As for profitability, Great Elm Capital Corp. has a trailing twelve months EPS of $1.37.
PE Ratio
Great Elm Capital Corp. has a trailing twelve months price to earnings ratio of 7.69. Meaning, the purchaser of the share is investing $7.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.31%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Sep 16, 2024, the estimated forward annual dividend rate is 1.4 and the estimated forward annual dividend yield is 13.3%.
Moving Average
Great Elm Capital Corp.’s worth is above its 50-day moving average of $10.37 and higher than its 200-day moving average of $10.48.
6. Tecnoglass (TGLS)
21.9% sales growth and 28% return on equity
Tecnoglass Inc., through its subsidiaries, manufactures, supplies, and installs architectural glass, windows, and associated aluminum products for the commercial and residential construction industries in North, Central, and South America. The company offers low emissivity, laminated/thermo-laminated, thermo-acoustic, tempered, silk-screened, curved, and digital print glass products. It also produces, exports, imports, and markets aluminum products, including bars, plates, profiles, rods, tubes, and other hardware that are used in the manufacture of architectural glass settings, such as windows, doors, spatial separators, and related products. In addition, the company provides curtain wall/floating facades, windows and doors, interior dividers and commercial display windows, hurricane-proof windows, stick facade systems, and other products, such as awnings, structures, automatic doors, and other components of architectural systems. It markets and sells its products primarily under the Tecnoglass, ES Windows, and Alutions brands through internal and independent sales representatives, as wells as directly to distributors. The company was founded in 1984 and is headquartered in Barranquilla, Colombia. Tecnoglass Inc. is a subsidiary of Energy Holding Corporation.
Earnings Per Share
As for profitability, Tecnoglass has a trailing twelve months EPS of $3.
PE Ratio
Tecnoglass has a trailing twelve months price to earnings ratio of 19.88. Meaning, the purchaser of the share is investing $19.88 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28%.
7. Workday (WDAY)
14.1% sales growth and 21.08% return on equity
Workday, Inc. provides enterprise cloud applications in the United States and internationally. Its applications help its customers to plan, execute, analyze, and extend to other applications and environments to manage their business and operations. The company offers a suite of financial management applications to maintain accounting information in the general ledger; manage financial processes, such as payables and receivables; identify real-time financial, operational, and management insights; enhance financial consolidation; reduce time-to-close; promote internal control and auditability; and achieve consistency across finance operations. It also provides spend management solutions that help organizations to streamline supplier selection and contracts, manage indirect spend, and build and execute sourcing events, such as requests for proposals; expense management solutions to submit and approve expenses; and a suite of human capital management applications that enables HR teams to hire, onboard, pay, develop, reskill, and provide employee experiences. In addition, the company offers planning applications; and applications for analytics and reporting comprising augmented analytics to surface insights to the line of business in simple-to-understand stories, machine learning to drive efficiency and automation, and benchmarks to compare performance against other companies. Further, it provides supply chain and inventory solutions to healthcare organizations; solutions to manage the end-to-end student and faculty lifecycle; and Workday Extend for customers and their developers to build custom applications. It serves professional and business services, financial services, healthcare, education, government, technology, media, retail, and hospitality industries. The company was formerly known as North Tahoe Power Tools, Inc. and changed its name to Workday, Inc. in July 2005. Workday, Inc. was incorporated in 2005 and is headquartered in Pleasanton, California.
Earnings Per Share
As for profitability, Workday has a trailing twelve months EPS of $5.21.
PE Ratio
Workday has a trailing twelve months price to earnings ratio of 50.61. Meaning, the purchaser of the share is investing $50.61 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.08%.
Volume
Today’s last reported volume for Workday is 1235180 which is 33.29% below its average volume of 1851640.
8. QCR Holdings (QCRH)
12.7% sales growth and 12.94% return on equity
QCR Holdings, Inc., a multi-bank holding company, provides commercial and consumer banking, and trust and asset management services. Its deposit products include noninterest-bearing demand, interest-bearing demand, time, and brokered deposits. The company also provides various commercial and retail lending/leasing, and investment services to corporations, partnerships, individuals, and government agencies. Its loan portfolio comprises loans to small and mid-sized businesses; business loans, including lines of credit for working capital and operational purposes; term loans for the acquisition of facilities, equipment, and other purposes; commercial and residential real estate loans; and installment and other consumer loans, such as home improvement, home equity, motor vehicle, and signature loans, as well as small personal credit lines. In addition, the company engages in leasing of machinery and equipment to commercial and industrial businesses under direct financing lease contracts; and issuance of trust preferred securities. It serves the Quad Cities, Cedar Rapids, Cedar Valley, Des Moines/Ankeny, and Springfield communities. The company was founded in 1993 and is headquartered in Moline, Illinois.
Earnings Per Share
As for profitability, QCR Holdings has a trailing twelve months EPS of $6.74.
PE Ratio
QCR Holdings has a trailing twelve months price to earnings ratio of 11.44. Meaning, the purchaser of the share is investing $11.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.94%.
